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ABSTRACT
Background: Basal Cell Carcinoma (BCC) is a type of skin cancer, and a growing number of cases are diagnosed each
year. There are many treatment options available, however finding the best treatment that has the lowest recurrence rate
and morbidity is a challenge. The treatment options vary from topical or systemic medications to special procedures to
surgical interventions. Treatment’s effectiveness largely differs on the BCC sub-type and its individual features. Method:
Data was collected from the charts of patients that were diagnosed with BCC. The selected patients were treated by either
Mosh surgery or Imiquimod. Results: Majority of patients who were diagnosed with BCC had light skin color. Some
patients had recurrence of the disease after Imiquimod treatment. However, no patient had any recurrence with Mohs
surgery. Conclusion: This study shows that Mohs surgery provides superior treatment outcome than many other options.
However, cost of the procedure can be an issue to patients with lower income or lack of proper health insurance.
Keywords: Basal cell carcinoma, Mohs surgery, Imiquimod, treatment options for BCC.

INTRODUCTION
Basal Cell Carcinoma (BCC) is a common forms of
human skin cancer, and have become a great public
health concern. Due to a rising rate of diagnosis and
high rate of morbidity from the disease, finding the
best treatment becomes an important priority.[1] Each
year, more than 5 million cases are diagnosed with
nonmelanoma skin cancer (NMSC). Among those
patients, 80% are basal cell carcinomas. Although,
mortality rate for these types of cancers are very
low; however, the number of cases are increasing,
which may be due to early diagnosis, higher sun
exposure and elderly patients are living longer.[2]
Basal cell carcinoma has high morbidity and
increased cost to health services, in spite of the low
death rate.[3] Nonmelanoma skin cancer is mainly
divided into basal cell carcinoma and squamous cell
carcinoma with an estimated cost $4.8 billion per
year.[4] The treatment options are determined largely
by how easily the tumors may be excised as well as
the lesion’s depth of penetration into the skin. The
following treatment options are available for
treatment of basal cell carcinoma.
Cryotherapy is a treatment that involves a fine mist
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of liquid nitrogen that freezes living tissue. This
effectively kills abnormal cells, in addition to normal
cells. The death of all the tissue in a small area will
make it possible for healthy cells to replenish the
dead tissue. Depending on how deep the lesion
protrudes, longer or shorter freeze thaw cycles may
be used to increase the chance of complete removal.
This is usually a quick, but rather painful treatment
that has been used as an initial treatment for many
cases. Cryosurgery is an effective treatment modality
for eyelid basal cell carcinomas, resulting in few
recurrences and good cosmetic and functional
outcomes at a low cost.[5] Compared with surgical
techniques, cryotherapy has a cure rate of 85 – 90%.
This is the main reason that it is less commonly
used.[6]
Imiquimod
(IMQ)
5%
cream
is
an
immunomodulatory and antitumorigenic agent,
which is used as a topical treatment regimen, who
had periocular basal cell carcinoma (BCC).[7] This is
typically not painful, but requires a longer period of
time for treatment to be successful. Duration of
treatment is usually about 6 weeks, and can be very
costly if the lesion is very large.[8]
Standard surgical excision is primarily done for most
cases.[9] The tumor is generally removed with a 4mm
vertical margin and the sample is sent to a
pathologist for examination via bread-loaf
microscopy. There is between a 1.5% and 28.5%
risk of incomplete removal which would be
recognized in the pathology report of the specimen
after surgery.[10] Errors may also take place on the
sectioning technique used by the pathologist. Bread-
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MATERIALS AND METHODS
A total of 60 patients’ charts from a local
dermatology clinic were reviewed for this study.
These patients received either Imiquimod or Mohs
surgery. Patients’ data including skin color, gender,
and age as well as cost, and treatment outcomes
were recorded. In Mohs surgery, once the skin was
removed, the entire sample was instantly prepped for
histological evaluation. The pathologist then
examined the sample to decide if the borders were
clear of malignancy. If not, the surgical mark was
expanded in the direction of its microscopic,
observable location. Patients were followed up in
one year after Mohs surgery.
In patients who received Imiquimod cream,
successful treatment was determined by a physician,
after a complete initial cycle of application 4-8
weeks, depending on the size and sub-type of BCC.
Imiquimod complete success was considered 1 year
after last application.

RESULTS
Out of 60 patients diagnosed with BCC, 45 patients
received Mohs surgery and 15 patients received
Imiquimod. Thirty-eight patients were men and 22
were women. Based on skin color type using the
Fitzpatrick’s scale, 17% were very pale white, 28%
were while/fair, 37% were white/olive, 13% were
medium/dark brown, and only 5% were very dark
brown/black. Of those that were diagnosed with
BCC, 7 patients were between the ages of 21 and 45
years, 17 patients were between 46 and 65 years and

the remaining 36 patients were over 65 years old.
None of the patients were under the age of 20 years.
The recurrence rate varied based on treatment
modality. There was no recurrence in patients who
received Mohs Surgery. Three patients who received
Imiquimod treatment had recurrent disease (20%).
Analysis of cost of both treatments showed that
Mohs surgery had the higher cost ($1,050) compared
with Imiquimod ($800). These fees were out of
pocked cost for patients and did not account for
insurance coverage.

DISCUSSION
Although, the most likely type of skin tone that was
diagnosed with BCC was white/olive presumably
due to decreased level of protection from melanin
pigment; however, the cancer also developed even in
patients with very dark/black skin. Additionally, age
was also a factor that seemed to play a part in BCC
diagnosis. According to data, prevalence was higher
in older population. This could be due to a
development of accumulated mutations over the
course of a longer time of life. Moreover, the skin
may not visibly show signs of damage until many
years later after exposure, especially if it is long-term
or consistent exposure. Furthermore, men were
almost twice as likely to be diagnosed with BCC
than females; however, it should also be noted that
this may not be necessarily due to genetic predisposition of the sexes. There are a variety of
factors to consider, such as, the possibility that men
may be less likely to notice an odd lump/lesion than
women possibly due to facial hair, or higher
exposure to UV radiation due to participation in
more outdoor activities.
The success of treatments was based of BCC
recurrence rates for each type of treatment. Only
three of the fifteen patients who were treated with
Imiquimod returned for recurrence; however,
Imiquimod is usually given to patients with smaller,
less severe lesions. The sample size was also small
in this case. Surgical excisions were more often
prescribed for the best outcomes as Imiquimod is a
relatively new treatment option. Thus, patients
receiving Imiquimod treatment, most likely had a
lesion that was not likely to pose as much of a risk or
the location made excisional surgery difficult to
carry out.
The most promising type of treatment was Mohs
Surgery because none of the treated patients had
recurrence of BCC. In standard surgical excision,
initial treatment is considered successful if the BCC
is determined to be completely removed via
microscopy. However, in the Mohs surgery, specific
training and personal judgment of the physician is
needed to remove the entire malignancy but at the
same time minimizing the amount of skin loss. It is
the best type of treatment for BCC, if it is done by a
careful, skilled professional on a proper candidate.
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loaf microscopy (vertical sections) does not examine
the margins to the extent it may need, and thus may
result in a possible overlook of a tumor nest existing
beyond the border of excision. This overlook would
then result in another round of excisions.[11] This
would result in additional surgery with extra cost, or
the cancer could persist and silently lurk throughout
the patient’s body.[12]
Mohs surgery is a more careful and precise
procedure, which allows for less significant defects
after treatment.[13] It is cost-effective, especially
when dealing with poorly demarcated, high-risk,
facial tumors, where it should be considered as the
first choice of treatment.[14] Five-year recurrence
rates using Kaplan-Meier survival analysis is very
low for previously untreated BCC.[15]
Radiotherapy can be used for facial lesions;
however, treatment failure is higher in aggressive
tumors and healing is delayed for weeks or even
months.[16]
Photodynamic therapy is useful for superficial
lesions only because it cannot properly penetrate to
deeper parts of skin.[16] The cure rate for PDT is
between 70 – 90%.[6]
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CONCLUSION
With so many cases of NMSC diagnosed each year,
research for diagnosis and treatments are essentially
vital. Although NMSC generally sees very high cure
rates and good cosmetic outcomes, it remains a
public health crisis due to the large number of people
effected. The treatment plans for a wide variety of
skin irregularities are usually similar, differing
mainly on how deep its protrusion is. Another
important factor for determining a treatment plan
includes the risk of incomplete removal. If a
pathology report even slightly hints that a lesion may
radiate outward in small abundance, its removal
must be done extremely carefully. Finally, the
physician must consider the outcome based on
appearance and/or lifestyle of the patient to
minimize the amounts and severity of defects after
treatment. Mohs surgery is the most successful
treatment option for BCC, even though it is more
expensive than alternative treatments. Future
direction is required to collect and analyze larger
sample data for recurrence rates of BCC since it is
largely categorized together, along with SCC within
the broader category of NMSC.
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When considering a proper candidate for treatment
options, it is determined at the discretion of the
physician. The physician would consider the size,
shape and color of the lesion as well as how deep it
may protrude. In addition, other factors to consider
for choosing the correct treatment option include
how long the lesion has been there as well as
patient’s age, medical history, and lifestyle.
The average billing for Mohs Surgery is higher than
Imiquimod. However, the cost of treatment varies
widely for different regions and countries.

